IL316002A - Compositions and methods for universal tumor cell killing - Google Patents

Compositions and methods for universal tumor cell killing

Info

Publication number
IL316002A
IL316002A IL316002A IL31600224A IL316002A IL 316002 A IL316002 A IL 316002A IL 316002 A IL316002 A IL 316002A IL 31600224 A IL31600224 A IL 31600224A IL 316002 A IL316002 A IL 316002A
Authority
IL
Israel
Prior art keywords
antigen binding
binding molecule
multispecific antigen
subject
tumor cell
Prior art date
Application number
IL316002A
Other languages
English (en)
Hebrew (he)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL316002A publication Critical patent/IL316002A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL316002A 2022-04-11 2023-04-11 Compositions and methods for universal tumor cell killing IL316002A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263329762P 2022-04-11 2022-04-11
US202263347330P 2022-05-31 2022-05-31
PCT/US2023/065627 WO2023201226A1 (en) 2022-04-11 2023-04-11 Compositions and methods for universal tumor cell killing

Publications (1)

Publication Number Publication Date
IL316002A true IL316002A (en) 2024-11-01

Family

ID=86286242

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316002A IL316002A (en) 2022-04-11 2023-04-11 Compositions and methods for universal tumor cell killing

Country Status (10)

Country Link
US (1) US20230357446A1 (cg-RX-API-DMAC10.html)
EP (1) EP4507790A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025512377A (cg-RX-API-DMAC10.html)
KR (1) KR20250004700A (cg-RX-API-DMAC10.html)
CN (1) CN119546329A (cg-RX-API-DMAC10.html)
AU (1) AU2023254191A1 (cg-RX-API-DMAC10.html)
CA (1) CA3247475A1 (cg-RX-API-DMAC10.html)
IL (1) IL316002A (cg-RX-API-DMAC10.html)
MX (1) MX2024012557A (cg-RX-API-DMAC10.html)
WO (1) WO2023201226A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗lag3抗體及其用途

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
WO1991007660A1 (en) 1989-11-13 1991-05-30 Children's Medical Center Corporation Non-invasive method for isolation and detection of fetal dna
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ATE267877T1 (de) 1993-01-07 2004-06-15 Sequenom Inc Dns - sequenzierung durch massenspektronomie
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
JPH08507926A (ja) 1993-03-19 1996-08-27 シーケノム・インコーポレーテツド エキソヌクレアーゼ分解を介した質量分析法によるdna配列決定
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
EP3018145B1 (en) 2010-10-27 2018-04-04 Amgen Research (Munich) GmbH Means and methods for treating dlbcl
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
MX2014003313A (es) 2011-09-23 2014-07-09 Amgen Res Munich Gmbh Moleculas de union biespecificas para 5t4 y cd3.
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
BR112014014591A8 (pt) 2011-12-12 2017-07-04 Baylor College Medicine processo para a expansão in vitro de células t específicas de antígeno, produto de células t autólogas ou alogênicas expandidas, composição farmacêutica, e, método de tratamento de um paciente, e, usos de uma linhagem de células engenheirada, de células dendríticas pulsadas com misturas de antígeno-peptídeo, de t-apcs pulsadas com misturas de antígeno-peptídeo/peptídeo, e de misturas de antígeno-peptídeo com pbmcs
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US9031642B2 (en) 2013-02-21 2015-05-12 Medtronic, Inc. Methods for simultaneous cardiac substrate mapping using spatial correlation maps between neighboring unipolar electrograms
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
AP2016009222A0 (en) 2013-11-04 2016-05-31 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
US20160326249A1 (en) 2014-01-15 2016-11-10 Zymeworks Inc. Bi-specific cd3 and cd19 antigen-binding constructs
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
PL3122781T3 (pl) 2014-03-28 2020-06-15 Xencor, Inc. Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
DK3189081T3 (da) 2014-09-05 2020-05-04 Janssen Pharmaceutica Nv Cd123-bindende midler og anvendelser deraf
EA201790719A1 (ru) 2014-09-26 2017-07-31 Макродженикс, Инк. Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
ES2809455T3 (es) 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
JP6696982B2 (ja) 2014-11-26 2020-05-20 ゼンコー・インコーポレイテッドXencor、 Inc. Cd3および腫瘍抗原に結合するヘテロ二量体抗体
MX384198B (es) 2014-12-19 2025-03-14 Chiome Bioscience Inc Proteina de fusion que comprende tres dominios de union a 5t4 y cd3.
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
CN107660214B (zh) 2015-01-08 2022-02-08 根马布股份公司 针对cd3和cd20的双特异性抗体
AR103488A1 (es) 2015-01-23 2017-05-10 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
HUE057285T2 (hu) 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
TWI811023B (zh) 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途
MY195059A (en) 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
EP3377112A4 (en) 2015-11-18 2019-06-12 Sorrento Therapeutics, Inc. CHEMICALLY BLOCKED BISPECIFIC ANTIBODIES
US20180305465A1 (en) 2015-11-25 2018-10-25 Amgen Inc. Heterodimeric antibodies that bind cd3 and cd38
RU2651776C2 (ru) 2015-12-01 2018-04-23 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") Биспецифические антитела против cd3*cd19
TW201720458A (zh) 2015-12-04 2017-06-16 宏觀基因股份有限公司 能夠結合cd19 和cd3 的雙特異性單價雙抗體以及其用途
EP3387013B1 (en) 2015-12-07 2022-06-08 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
ES2954153T3 (es) 2015-12-22 2023-11-20 Regeneron Pharma Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer
UA126657C2 (uk) 2016-02-03 2023-01-11 Емджен Рісерч (Мюнік) Ґмбг ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font>
EP3464365A1 (en) 2016-06-01 2019-04-10 Xencor, Inc. Bispecific antibodies that bind cd123 and cd3
WO2017210485A1 (en) 2016-06-01 2017-12-07 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma
RU2019102008A (ru) 2016-06-28 2020-07-28 Ксенкор, Инк. Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至cd3和cd123的雙特異性抗體樣結合蛋白
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗gprc5d抗體、結合gprc5d與cd3之雙特異性抗原結合分子及其用途
KR102520731B1 (ko) 2016-09-23 2023-04-14 리제너론 파아마슈티컬스, 인크. 항-steap2 항체, 항체-약물 컨쥬게이트, 및 steap2 및 cd3에 결합하는 이중특이적 항원-결합 분자, 및 이의 용도
KR102531251B1 (ko) 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
US11124577B2 (en) 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
EP3541843A1 (en) 2016-11-15 2019-09-25 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
KR102692708B1 (ko) 2016-12-20 2024-08-07 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
CN108690138A (zh) 2017-04-12 2018-10-23 鸿运华宁(杭州)生物医药有限公司 一种能与人cd19或cd20和人cd3结合的双特异性抗体及其应用
WO2018223004A1 (en) 2017-06-01 2018-12-06 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
JP2020521791A (ja) 2017-06-02 2020-07-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のためのii型抗cd20抗体及び抗cd20/cd30二重特異性抗体
WO2019050521A1 (en) 2017-09-07 2019-03-14 Macrogenics, Inc. DOSAGE SCHEMES OF BISPECIFIC DIACORPS CD123 X CD3 IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES
CN109535257B (zh) 2017-09-22 2021-05-28 同润生物医药(上海)有限公司 新型双特异性cd3/cd19多肽复合物
CA3078969A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
CN107903324B (zh) 2017-11-15 2021-01-29 北京绿竹生物技术股份有限公司 一种结合人cd19和cd3的双特异性抗体
BR112020015052A2 (pt) 2018-02-09 2020-12-08 Genmab A/S Composição farmacêutica, uso da composição farmacêutica, métodos para tratar câncer em um sujeito, para preparar uma composição farmacêutica e para preparar uma forma de dosagem unitária, forma de dosagem unitária, recipiente, e, kit-de-partes
MA52152A (fr) 2018-03-12 2021-01-20 Genmab As Anticorps
EP3773621A4 (en) 2018-03-27 2022-03-23 Systimmune, Inc. GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE
CA3098516A1 (en) 2018-04-27 2019-10-31 Novartis Ag Dosing of a bispecific antibody that bind cd123 and cd3
WO2019220368A1 (en) 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
PL3796912T3 (pl) 2018-05-23 2023-09-11 Celgene Corporation Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego
EP3802622A4 (en) 2018-05-29 2021-08-18 Wuxi Biologics Ireland Limited NEW BISPECIFIC ANTI-CD3 / ANTI-CD20 ANTIBODY
CN112512578A (zh) 2018-06-01 2021-03-16 诺华股份有限公司 结合cd123和cd3的双特异性抗体的给药
CN113195544A (zh) 2018-06-07 2021-07-30 库利南肿瘤股份有限公司 多特异性结合蛋白及其使用方法
TW202504917A (zh) 2018-06-21 2025-02-01 美商再生元醫藥公司 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法
TW202019965A (zh) 2018-07-16 2020-06-01 美商安進公司 治療多發性骨髓瘤之方法
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAx抗-CD3抗體及其用途
MX2021001083A (es) 2018-07-31 2021-03-31 Amgen Res Munich Gmbh Regimen posologico para anticuerpos biespecificos contra bcma-cd3.
ES3009025T3 (en) 2018-08-31 2025-03-25 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
TWI856979B (zh) 2018-10-09 2024-10-01 法商賽諾菲公司 三特異性抗cd38、抗cd28和抗cd3結合蛋白和用於治療病毒感染的使用方法
MX2021004868A (es) 2018-10-30 2021-09-08 Macrogenics Inc Diacuerpos cd123 x cd3 biespecificos para el tratamiento de neoplasias hematologicas.
BR112021008486A2 (pt) 2018-11-01 2021-10-26 Shandong New Time Pharmaceutical Co., Ltd Anticorpo biespecífico e seu uso
KR20210104836A (ko) 2018-12-19 2021-08-25 리제너론 파아마슈티컬스, 인크. 이중 특이적 항-cd28 x 항-cd22 항체 및 그의 용도
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
EP3917969A4 (en) 2019-01-28 2023-02-01 Wuxi Biologics Ireland Limited NEW BISPECIFIC CD3/CD20 POLYPEPTIDIC COMPLEXES
EP3930850A1 (en) 2019-03-01 2022-01-05 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용

Also Published As

Publication number Publication date
WO2023201226A1 (en) 2023-10-19
CN119546329A (zh) 2025-02-28
MX2024012557A (es) 2024-12-06
KR20250004700A (ko) 2025-01-08
CA3247475A1 (en) 2023-10-19
EP4507790A1 (en) 2025-02-19
JP2025512377A (ja) 2025-04-17
US20230357446A1 (en) 2023-11-09
AU2023254191A1 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
Niu et al. Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC
De Lima et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
Liu et al. Immunotherapies for hepatocellular carcinoma
Agarwala et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma
Roberts et al. Systemic use of tumor necrosis factor alpha as an anticancer agent
Abdel-Wahab et al. Adverse events in cancer immunotherapy
Haas et al. Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies
Li et al. Firing up “cold” tumors: Ferroptosis causes immune activation by improving T cell infiltration
KR20140038382A (ko) 암의 치료 증대를 위한 국소 면역조절 치료제와 전신 면역조절 치료제의 복합제
WO2016019969A1 (en) Subcutaneously administered bispecific antibodies for use in the treatment of cancer
Weide et al. Intralesional treatment of metastatic melanoma: a review of therapeutic options
Wang et al. Immunogenic chemotherapy effectively inhibits KRAS-Driven lung cancer
US20200377596A1 (en) Dosing of bispecific t cell engager
Wang et al. Safety, pharmacokinetics, and pharmacodynamics evaluation of ivonescimab, a novel bispecific antibody targeting pd‐1 and vegf, in chinese patients with advanced solid tumors
Zhang et al. Self-assembled natural triterpenoids for the delivery of cyclin-dependent kinase 4/6 inhibitors to enhance cancer chemoimmunotherapy
Vidovic et al. Case report: combined intra-lesional IL-2 and topical imiquimod safely and effectively clears multi-focal, high grade cutaneous squamous cell cancer in a combined liver and kidney transplant patient
Wang et al. Absorbable microspheres sustaining epirubicin and TLR7 agonist release for transarterial chemo-immuno-embolization in liver tumor
US20230121320A1 (en) Sting agonist combination treatments with cytokines
US20210380695A1 (en) Sting agonist combination treatments with immune checkpoint inhibitors
JP2023533111A5 (cg-RX-API-DMAC10.html)
US20200101076A1 (en) Pharmaceutical compositions for prevention or treatment of cytokine release syndrome
Choi et al. Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding
US12240904B2 (en) Use of anti-PD-1 antibody in combination with famitinib in preparation of drug for treating tumors
CN113905764B (zh) 用于治疗癌症的前体半胱天冬酶-3活化作用和免疫疗法
WO2022217082A1 (en) Dosing of bispecific t cell engager